You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cell Cycle Progression Test

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in United States (Prolaris Testing)

Terminated
  • Prostate Cancer
  • Prolaris Testing
  • Homewood, Alabama
  • +33 more
Jun 17, 2022

Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor Trial in Petaling Jaya (Dendritic cell + Cytokine-induced killer cell

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Advanced Solid Tumor
  • Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy
  • Tegafur Only Product
  • Petaling Jaya, Kuala Lumpur, Malaysia
    Clinical Oncology Department, Ummc
Jul 12, 2023

NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Phase I - Mirdametinib - Level 1
  • +4 more
  • (no location specified)
Jul 7, 2023

Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)

Not yet recruiting
  • Urothelial Carcinoma
  • Naptumomab Estafenatox
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
May 30, 2023

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

DLBCL Trial (Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day

Approved for marketing
  • DLBCL
  • Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
  • (no location specified)
Aug 26, 2020

Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Fungoides Mycosis Sezary Syndrome
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Jul 13, 2023

Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell

Not yet recruiting
  • Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +5 more
  • (no location specified)
Jul 13, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

AL Amyloidosis Trial (procedure, drug, other)

Not yet recruiting
  • AL Amyloidosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +15 more
  • (no location specified)
Aug 28, 2023

Persistent or Recurrent Cutaneous T-Cell Lymphoma Trial in Australia, Puerto Rico, United States (E7777 9 mcg/kg)

Completed
  • Persistent or Recurrent Cutaneous T-Cell Lymphoma
  • E7777 9 mcg/kg
  • Birmingham, Alabama
  • +21 more
Dec 5, 2022

Arthritis, Rheumatoid Trial in Rancagua (Placebo, Omega-3, Aerobic exercise)

Active, not recruiting
  • Arthritis, Rheumatoid
  • Placebo
  • +2 more
  • Rancagua, Libertador Bernardo O'Higgins, Chile
    Universidad de O'Higgins
Jul 11, 2023

Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab, Pembrolizumab biosimilar)

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • (no location specified)
Dec 19, 2022

MDS Trial in Saint Louis (DEC-C, MyeloSeq-HD)

Recruiting
  • Myelodysplastic Syndromes
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 18, 2023

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Lung Cancer, Non Small Cell Lung Cancer, Adenocarcinoma of Lung Trial run by the National Cancer Institute (NCI) (LMB-100,

Active, not recruiting
  • Lung Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 4, 2022

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 7, 2023

Head and Neck Squamous Cell Carcinoma Trial (Carrilizumab, bevacizumab,capecitabine)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Carrilizumab, bevacizumab,capecitabine
  • (no location specified)
Jul 20, 2023

Pancreatic Tumors Trial in Shanghai (Sofantinib?abraxane?gemcitabine, Abraxane combined with gemcitabine)

Not yet recruiting
  • Pancreatic Neoplasms
  • Shanghai, China
    Fudan University ShangHai Cancer Center
Jul 31, 2023

Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer Trial in Nashville (drug, biological, radiation, procedure)

Not yet recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • Stage IV Lung Cancer
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Oct 25, 2023

Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Cadonilimab combined Anlotinib
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023

Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

Not yet recruiting
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Boston, Massachusetts
  • +1 more
Apr 4, 2023